Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer

Histopathology

Volumn 62, Issue 2, 2013, Pages 267-274

  Huo, Lei ^a   Zhang, Jinxia ^a   Gilcrease, Michael Z ^a   Gong, Yun ^a   Wu, Yun ^a   Zhang, Hong ^a   Resetkova, Erika ^a   Hunt, Kelly K ^a   Deavers, Michael T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

GCDFP 15; Immunohistochemistry; Mammaglobin A; Triple negative

Indexed keywords

GROSS CYSTIC DISEASE FLUID PROTEIN 15; MAMMAGLOBIN A; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST METASTASIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STAINING; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARRIER PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMAGLOBIN A; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84871116041     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04344.x     Document Type: Article

References (30)

1. Chaignaud B, Hall TJ, Powers C, Subramony C, Scott-Conner CE. Diagnosis and natural history of extramammary tumors metastatic to the breast. J. Am. Coll. Surg. 1994; 179; 49-53.
2. Hadju SI, Urban JA. Cancers metastatic to the breast. Cancer 1972; 29; 1691-1696.
3. McCrea ES, Johnston C, Haney PJ. Metastases to the breast. AJR Am. J. Roentgenol. 1983; 141; 685-690.
4. Sanderson AT. Metastatic tumours in the breast. Br. J. Surg. 1959; 47; 54-58.
5. Lee BH, Hecht JL, Pinkus JL, Pinkus GS. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am. J. Clin. Pathol. 2002; 117; 745-750.
6. Ollayos CW, Riordan GP, Rushin JM. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch. Pathol. Lab. Med. 1994; 118; 630-632.
7. Yokozaki H, Takekura N, Takanashi A, Tabuchi J, Haruta R, Tahara E. Estrogen receptors in gastric adenocarcinoma: a retrospective immunohistochemical analysis. Virchows Arch. A Pathol. Anat. Histopathol. 1988; 413; 297-302.
8. Haagensen DE Jr, Mazoujian G. Biochemistry and immunohistochemistry of gross cystic disease fluid proteins of the breast. In Haagensen CD ed. Diseases of the breast, 3rd edn. Philadelphia, PA: Saunders, 1986; 474-500.
9. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uterglobin gene family, is overexpressed in human breast cancer. Cancer Res. 1996; 56; 860-865.
10. Sapino A, Cassoni P, Bussolati G. Gross cystic disease fluid protein (GCDFP-15) in the breast: past and present. J. Biol. Regul. Homeost. Agents 2000; 14; 259-262.
11. Zehentner BK, Carter D. Mammaglobin: a candidate diagnostic marker for breast cancer. Clin. Biochem. 2004; 37; 249-257.
12. Wick MR. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum. Pathol. 1989; 20; 281-287.
13. Han JH, Kang Y, Shin HC et al. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. Arch. Pathol. Lab. Med. 2003; 127; 1330-1334.
14. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod. Pathol. 2010; 23; 654-661.
15. Wang LJ, Greaves WO, Sabo E et al. GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Appl. Immunohistochem. Mol. Morphol. 2009; 17; 505-511.
16. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin versus GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am. J. Clin. Pathol. 2007; 127; 103-113.
17. Zafrakas M, Petschke B, Donner A et al. Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies. BMC Cancer 2006; 6; 88.
18. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod. Pathol. 2007; 20; 208-214.
19. Wang Z, Spaulding B, Sienko A et al. Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int. J. Clin. Exp. Pathol. 2009; 2; 384-389.
20. Watson MA, Dintzis S, Darrow CM et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res. 1999; 59; 3028-3031.
21. Al-Joudi FS, Kaid FA, Ishak I, Mohamed N, Osman K, Alias IZ. Expression of human mammaglobin and clinicopathologic correlations in breast cancer: the findings in Malaysia. Indian J. Pathol. Microbiol. 2011; 54; 284-289.
22. Lewis GH, Subhawong AP, Nassar H et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am. J. Clin. Pathol. 2011; 135; 587-591.
23. Fritzsche FR, Thomas A, Winzer KJ et al. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol. Histopathol. 2007; 22; 1221-1230.
24. Park SY, Kim BH, Kim JH, Lee S, Kang GH. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch. Pathol. Lab. Med. 2007; 131; 1561-1567.
25. Guan XF, Hamedani MK, Adeyinka A et al. Relationship between mammaglobin expression and estrogen receptor status in breast tumors. Endocrine 2003; 21; 245-250.
26. Chia SY, Thike AA, Cheok PY, Tan PH. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors. Breast 2010; 19; 355-359.
27. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 2010; 134; 907-922.
28. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007; 131; 18-43.
29. Matsuoka K, Ohsumi S, Takashima S, Saeki T, Aogi K, Mandai K. Occult breast carcinoma presenting with axillary lymph node metastases: follow-up of eleven patients. Breast Cancer 2003; 10; 330-334.
30. Raica M, Cîmpean AM, Meche A, Alexa A, Suciu C, Mureşan A. Analysis of the immunohistochemical expression of mammaglobin A in primary breast carcinoma and lymph node metastasis. Rom. J. Morphol. Embryol. 2009; 50; 341-347.